Glioblastoma is the most common form of brain cancer, and given that activated MET signaling/ MET alteration contributes significantly to glioblastoma 82, a thorough understanding of the MET signaling pathway is required to identify functional therapeutic targets to aid the development of effective treatment for this disease. The gene discussed is MET; the disease is glioblastoma.